Gilead Sciences Announces Expiration Of HSR Waiting Period For CymaBay Tender Offer

Written by Emily J. Thompson, Senior Investment Analyst

GILD+3.01%

CBAY%

Source: Business Insider

Updated: Mar 11 2024

0mins

Source: Business Insider

GILD

$124.91+Infinity%1D

Analyst Views on GILD

Wall Street analysts forecast GILD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 135.00 USD with a low forecast of 105.00 USD and a high forecast of 150.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

19 Analyst Rating

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 121.260

Low

105.00

Averages

135.00

High

150.00

Current: 121.260

Low

105.00

Averages

135.00

High

150.00

BofA

Buy

maintain

$144 -> $154

Al Analysis

2026-01-09

Reason

BofA

Price Target

$144 -> $154

Al Analysis

2026-01-09

maintain

Buy

Reason

BofA raised the firm's price target on Gilead to $154 from $144 and keeps a Buy rating on the shares. The firm, which switched its valuation method, says the company's "steady" HIV franchise growth remains core to its Buy thesis as it sees upside from recent and upcoming launches.

UBS

Michael Yee

Neutral -> Buy

upgrade

$112 -> $145

2026-01-07

Reason

UBS

Michael Yee

Price Target

$112 -> $145

2026-01-07

upgrade

Neutral -> Buy

Reason

UBS analyst Michael Yee upgraded Gilead to Buy from Neutral with a price target of $145, up from $112, after assuming coverage of the name. The firm cites its expectations for "strong" HIV pre-exposure prophylaxis sales from Yeztugo for the upgrade. This should drive revenue and earnings upside as well as increasing confidence in Gilead's outer-year growth, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD

Unlock Now

Citi

Geoff Meacham

Buy

maintain

$135 -> $140

2026-01-07

Reason

Citi

Geoff Meacham

Price Target

$135 -> $140

2026-01-07

maintain

Buy

Reason

Citi analyst Geoff Meacham raised the firm's price target on Gilead to $140 from $135 and keeps a Buy rating on the shares.

Morgan Stanley

Overweight

maintain

$147 -> $151

2025-12-12

Reason

Morgan Stanley

Price Target

$147 -> $151

2025-12-12

maintain

Overweight

Reason

Morgan Stanley raised the firm's price target on Gilead to $151 from $147 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

About GILD

Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.